Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria Contact:

Investor Relations and Media:  
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Finlay Minerals Ltd. reports on its Annual General & Special Meeting

Finlay Minerals Ltd. reports on its Annual General & Special Meeting

finlay minerals ltd. (TSXV: FYL) (OTCQB: FYMNF) (" Finlay " or the " Company ") reports that all matters set before the Annual General and Special Meeting of Shareholders of the Company held on Friday, June 20, 2025 (the " Meeting ") were approved by the shareholders. An aggregate of 74,155,953 common shares of the Company (" Common Shares ") were voted representing 51.94% of the issued and outstanding Common Shares as at the Record Date of May 16, 2025 .

Finlay Minerals Ltd. logo (CNW Group/Finlay Minerals Ltd.)

The six nominees for the Board of Directors were elected at the Meeting and they are: John A. Barakso , Robert F. Brown , Alvin W. Jackson , Ilona Barakso Lindsay , David A. Schwartz , and Kristina Walcott .

Additionally, the reappointment of De Visser Gray LLP, Chartered Professional Accountants, as auditors for the Company and the Company's 10% Rolling Stock Option Plan were approved by shareholders.

Subsequent to the Meeting, the Board of Directors also re-appointed the following officers for a further year:

Robert F. Brown

Executive Chairman of the Board

Ilona B. Lindsay

President & Chief Executive Officer

Gord Steblin

Chief Financial Officer

David Schwartz

Corporate Secretary

Wade Barnes

Vice President, Exploration

Susan Flasha

Vice President, Corporate Development.

About finlay minerals ltd.

Finlay is a TSXV company focused on exploration for base and precious metal deposits with five 100% owned properties in northern British Columbia : the PIL and ATTY properties in the Toodoggone (13,374 hectares ("ha")), the Silver Hope Cu-Ag Property (21,322 ha) and the SAY Cu-Ag & the JJB Cu Properties (41,655 ha) in the Bear Lake Corridor. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries.

The PIL and ATTY Properties are fully and sole funded by Freeport-McMoRan through 6-year Earn-In Agreements; the JJB, SAY and Silver Hope 2025 exploration programs are fully funded by Finlay.

Finlay trades under the symbol "FYL" on the TSXV and under the symbol "FYMNF" on the OTCQB. For further information and details, please visit the Company's website at www.finlayminerals.com

On behalf of the Board of Directors,

Robert F. Brown , P. Eng.
President, Executive Chairman of the Board & Director

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as "expect", "plan", "anticipate", "project", "target", "potential", "schedule", "forecast", "budget", "estimate", "intend" or "believe" and similar expressions or their negative connotations, or that events or conditions "will", "would", "may", "could", "should" or "might" occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, corporate plans. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay's proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law.

SOURCE finlay minerals ltd.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/25/c1152.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Bold Ventures Announces Closing of Its Fully Subscribed, Upsized Non-Brokered Private Placement

Bold Ventures Announces Closing of Its Fully Subscribed, Upsized Non-Brokered Private Placement

Bold Ventures Inc. (TSXV: BOL) (the "Company" or "Bold") is pleased to announce the fourth and final closing of its non-brokered private placement offering first announced on April 11th and increased on May 26th and June 5th, of up to 9,000,000 working capital units (the "WC Units") of the Company at a price of $0.05 per WC Unit for up to $450,000, and up to 10,314,666 Flow Through Units (the "FT Units") at a price of $0.06 per FT Unit for up to $618,900, both of which constitute the "Offering". The Offering was fully subscribed for gross proceeds of $1,068,900.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Questcorp Mining Announces Commencement of Phase 1 Work at the La Union Gold Project

Questcorp Mining Announces Commencement of Phase 1 Work at the La Union Gold Project

Questcorp Mining Inc. (CSE: QQQ) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") is pleased to announce the commencement of the first phase work program at its La Union carbonate replacement deposit (CRD) project, located in Sonora, Mexico. Questcorp is earning a 100% interest from Riverside Resources Inc. in the 2,520 ha (25 km sq) property by making a series of cash payments and share issuance and completing a series of exploration expenditures.

The initial stages of phase one will concentrate on finalizing the location of drill targets and drill pads for the upcoming drill program. Field activities are underway and include:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×